1. Home
  2. EIC vs XBIT Comparison

EIC vs XBIT Comparison

Compare EIC & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

EIC

Eagle Point Income Company Inc.

HOLD

Current Price

$9.42

Market Cap

228.8M

Sector

Finance

ML Signal

HOLD

Logo XBiotech Inc.

XBIT

XBiotech Inc.

N/A

Current Price

$2.17

Market Cap

66.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EIC
XBIT
Founded
N/A
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Pharmaceuticals and Biotechnology
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
228.8M
66.8M
IPO Year
2018
2015

Fundamental Metrics

Financial Performance
Metric
EIC
XBIT
Price
$9.42
$2.17
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
★ $12.63
N/A
AVG Volume (30 Days)
★ 92.1K
43.6K
Earning Date
05-27-2026
05-08-2026
Dividend Yield
★ 13.25%
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$9.08
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$9.17
$2.09
52 Week High
$13.55
$3.44

Technical Indicators

Market Signals
Indicator
EIC
XBIT
Relative Strength Index (RSI) 24.23 40.04
Support Level $9.33 N/A
Resistance Level $10.14 $2.48
Average True Range (ATR) 0.13 0.04
MACD -0.04 0.00
Stochastic Oscillator 2.67 15.38

Price Performance

Historical Comparison
EIC
XBIT

About EIC Eagle Point Income Company Inc.

Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.

About XBIT XBiotech Inc.

XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.

Share on Social Networks: